Skip to main content

Antibe Announces Completion of Sale

Written by Customer Service on . Posted in Mergers And Acquisitions.

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) announced that, in connection with its previously announced receivership proceedings, the Company completed a transaction (the “Transaction”) on March 17, 2025 whereby Taro Pharmaceuticals Inc. (the “Purchaser”) purchased all of the issued and outstanding common shares of the Company from FTI Consulting Inc. (the “Receiver”), in its capacity as court-appointed receiver and manager of the Company, pursuant to a transaction agreement (the “Transaction Agreement”) dated January 15, 2025.

On January 29, 2025, the Superior Court of Justice (Commercial List) (the “Court”) granted an order under section 101 of the Courts of Justice Act pursuant to which the Court, among other things, approved the Transaction Agreement and also (i) added 1001138302 Ontario Ltd. (“Residual Co”) as part of the receivership proceedings; (ii) authorized the transfer and vesting of all of the right, title and interest of the Company in certain excluded assets and liabilities in Residual Co; (iii) authorized the Company to file articles of reorganization, if required; (iv) authorized and directed the Corporation to issue an aggregate of 100 newly issued common shares representing 100% of the issued and outstanding common shares of the Company to the Purchaser; and (v) authorized the termination and cancellation of all of the other equity interests of the Company for no consideration.

On March 6, 2025, an order was issued by the Ontario Securities Commission (“OSC”) for the partial revocation of the failure-to-file cease trade order (“FFCTO”) issued by the OSC on July 10, 2024 as a result of the Company’s failure to file certain continuous disclosure documents. The Company has filed with the OSC an application for a full revocation of the FFCTO and an application to cease to be a reporting issuer in each of Alberta, British Columbia, Manitoba, Ontario and Saskatchewan.

Additional information regarding the Company’s receivership proceedings and the Transaction can be found on the Receiver’s website at http://cfcanada.fticonsulting.com/antibe/.

Notice regarding forward-looking statements

This press release contains forward-looking information within the meaning of Canadian securities laws. Such forward-looking information includes, without limitation, statements relating to the Company’s application for a full revocation of the FFCTO and to cease to be a reporting issuer in each of Alberta, British Columbia, Manitoba, Ontario and Saskatchewan. Forward-looking information is subject to known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those expressed or implied by the forward-looking information. Such risks include the failure of the Company to satisfy the securities regulatory requirements for obtaining the full revocation order and/or the cease to be a reporting issuer order. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that forward-looking information contained in this press release are made as of the date of this press release. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:
(416) 922-3460

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.